Potential to be the leading Treatment for Oral Pain

Our lead indication is for pain caused by Oral Mucositis and BupiZenge^™ contains the effective non-opioid long acting reliever bupivacaine. By applying bupivacaine in a lozenge we effectively relieves pain locally in the mouth and throat which solves this unmet medical need.

Rapid pain relief

Studies of BupiZenge^™ has shown significant pain relief within minutes and lasting for hours.

Building on the well-known and researched active component bupivacaine, used for decades in surgery, dental procedures and epidural at child birth.

Oral
mucositis

Oral mucositis is a painful side effect from radiotherapy and chemotherapy. In som cancers nearly all patients develop oral mucositis. Different cancer types and chemotherapy treatments result in different severities 1-4 on WHO’s toxicity scale.

Agonizing pain

No escape

Patients experience varying degrees and severity of oral mucositis depending on cancer type and chemotherapy treatment. For some cancers like Head and Neck Cancer (HNC) 90% of all patients suffer from oral mucositis, with no good treatment options.

Quality of life

Debilitating pain has significantly negative impacts to quality of life. Studies have shown significant impacts to patients’ mental, physical and social well being due to the oral pain.

Affecting outcomes

Severe oral pain left untreated impact patients’ ability to eat, drink, sleep and socialize. Interrupted or reduced treatments and weight loss will impact cancer patients’ prognosis for recovery.

Patient testimony

”I was able to eat a sandwich during the study, which is something I haven’t been able to do in weeks due to the pain. And I was able to talk for extended periods of time without any discomfort.”

Potential to become the leading treatment for oral pain

OncoZenge holds a number of patents safeguarding
the innovation in and around our product application. There is a large commercial opportunity for OncoZenge and strategic partners in progressing our drug candidate to market.

Oral Mucositis

Mouth and throat surgery e.g. tonsillectomy

Dental applications

Endoscopy

Chronic pain (Burning Mouth Syndrome)

Dry mouth (Sjögren’s Syndrome)

Oral ulcerations (Behcet’s disease)

Oral inflammation (Oral Lichen planus)

Our lead indication is the condition oral mucositis, a market opportunity
in itself measuring hundreds of millions of dollars annually, even with conservative assumptions. The opportunity is global and an effective sales and distribution can reach millions of patients quickly considering the lack of good treatment options and the large unmet medical need.

Oral pain is a broader opportunity however, and a motivated partner may develop through incremental studies and approvals offer BupiZenge^™ also for other uses. Such as general oral pain, endoscopy or dental applications, mouth and throat surgery such as tonsil removal, chronic pain such as Burning Mouth Syndrome (BMS) and more rare conditions such as Behcet’s disease or Oral Lichen Planus.

BupiZenge^™ offers near term opportunities and long term growth potential.

Market research confirms the need for BupiZenge^™

Dr Pooja Nandwani Patel, Head of Department of Radiation Oncology, Sterling Cancer Hospital

Radiotherapy and chemotherapy act independently in determining acute mucosal toxicity and concurrent RT-CT increases the mucositis grades and incidence almost 4 times more…

Show full quote

Radiotherapy and chemotherapy act independently in determining acute mucosal toxicity and concurrent RT-CT increases the mucositis grades and incidence almost 4 times more. Mucositis affects outcomes in many ways – increases workload with admissions, treatment delays with incomplete treatments, sometimes requiring replannings thereby increasing costs directly or indirectly & affecting outcomes as well. Till date there are no clear guidelines for prevention of oral mucositis with CT+RT. Constant oral rinsing & salivary substitutes, proper nutrition and supportive care, taking care of infection and good use of opioid analgesics and steroids especially in the last two weeks is the key to phase off the menace from so called and mostly ignored symptom – mucositis. Oral Care Protocols should be strictly implemented with the institutional guidelines set by the multidisciplinary team

Stephen T. Sonis, DMD. DMSc , Professor of Oral Medicine, Harvard

Oral mucositis remains a devastatingly painful complication for many patients being treated with anti-cancer cytotoxic chemo- or radiotherapy…

Show full quote

Oral mucositis remains a devastatingly painful complication for many patients being treated with anti-cancer cytotoxic chemo- or radiotherapy. Aside from its symptomatic toll, poorly controlled pain negatively impacts patients’ ability to tolerate optimal cancer treatment, as well as compromising nutrition and adding to the cost of care. The Phase 2 clinical trial results reported by OncoZenge suggest that a novel topical formulation of bupivacaine might offer a safe and effective, non-opioid alternative to mitigating mucositis-associated pain. I look forward to collaborating with OncoZenge to confirm their findings and make this technology a treatment option available to all those patients who need it.

Bupivacaine safety data

Bupivacaine is a local anesthetic that is used to block pain signals from being sent to the brain. It is commonly used in dental procedures, surgery, and childbirth. Bupivacaine the maximum recommended daily human dose is (400 mg) This means that the total amount of bupivacaine that can be safely given to a patient in a 24-hour period is 400 mg. Our BupiZenge™ lozenge is 25 mg and recommended to give 5 times daily, ahead of meals.

Reference: https://www.accessdata.fda.gov/…./071165s020lbl.pdf

The systemic uptake of bupivacaine decreases with injection technique and injection time. This means that the amount of bupivacaine that enters the bloodstream is lower when it is injected slowly and with care.

Lozenges are a type of medication that dissolves slowly in the mouth. This means that the absorption of bupivacaine is slower when it is taken in lozenge form. This provides an additional margin of safety, as it means that less bupivacaine enters the bloodstream.

There is no risk of accidental (intravasal) high or/and fast exposure with lozenges that slowly dissolve. This is because the bupivacaine is released slowly into the bloodstream over time. If a lozenge is swallowed, the absorption of bupivacaine is even lower in the ventricle than in the mouth. This is because the pH in the ventricle is lower than in the mouth, which makes it more difficult for bupivacaine to be absorbed.

Research and publications

Read all the clinical studies and publications made on bupivacaines effects as a lozenge

Learn more

Potential to be the leading Treatment for Oral Pain

Rapid pain relief

Oral
mucositis